The functional state of the respiratory system of the patients with proximal spinal muscular atrophy 5q (SMA 5q): from the natural history of the disease to the era of pathogenetic therapy. Problems and expectations

   Proximal spinal muscular atrophy 5q is an autosomal recessive neuromuscular disease. This disorder is characterized by progressive symptoms of flaccid paralysis and muscular atrophy due to degeneration of α-motor neurons in the anterior horns of the spinal cord. The disease is caused by the lack of a fully functional SMN protein due to homozygous deletion of exon 7 in the SMN1 gene. For a long time, spinal muscular atrophy was the leading genetic cause of infant mortality. With the introduction of modern pathogenetic treatment methods that modify the disease, the duration and quality of life of patients increases, and a “blurring of boundaries” between types of spinal muscular atrophy and the formation of new phenotypes happens. In this regard, approaches to patient management, including approaches to the assessment and correction of respiratory disorders, are changing. The review of the available medical literature was conducted. The clinical studies on spinal muscular atrophy in the natural course of the disease and with the use of pathogenetic drugs were analyzed, as well as the data on the state of the respiratory system of the patients.

1. Anisimova I.V., Artemyeva S.B., Belousova E.D., Vlodavets D.V., Volsky G.B., Germanenko O.Yu. et al. Proximal spinal muscular atrophy 5q. Guidelines, 2023; 118. (in Russ.)

2. Kolb S.J., Coffey C.S., Yankey J.W., Krosschell K., Arnold W.D., Rutkove S.B. et al. NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol 2017; 82(6): 883–891. DOI: 10.1002/ana.25101

3. Cances C., Vlodavets D., Comi G.P., Masson R., Mazurkiewicz-Bełdzińska M., Saito K. et al.; ANCHOVY Working Group. Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study. Orphanet J Rare Dis 2022; 17(1): 300. DOI: 10.1186/s13023–022–02455-x

4. Fauroux B., Khirani S., Griffon L., Teng T., Lanzeray A., Amaddeo A. Non-invasive Ventilation in Children With Neuromuscular Disease. Front Pediatr 2020; 8: 482. DOI: 10.3389/fped.2020.00482.

5. Babak S.L. Noninvasive ventilation. A practical guide to respiratory medicine. M.: TRIMM Group of Companies, 2020; 335. (in Russ.)

6. Hull D., Aniapravan R., Chan E., Chetwin M., Forton D., Gallagher D. et al. Guide to Respiratory Support for Children with Neuromuscular Diseases, 2015; 207. (in Russ.)

7. Darras B.T., Monani U.R., De Vivo D.C. Genetic Disorders Affecting the Motor Neuron. Swaiman’s Pediatr Neurol 2017; 6: 1057–1064. DOI: 10.1016/b978–0–323–37101–8.00139–9

8. Finkel R.S., McDermott M.P., Kaufmann P., Darras B.T., Chung W.K., Sproule D.M. et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 2014; 83(9): 810–817. DOI: 10.1212/WNL.0000000000000741

9. De Sanctis R., Coratti G., Pasternak A., Montes J., Pane M., Mazzone E.S. et al. Developmental milestones in type I spinal muscular atrophy. Neuromuscul Disord 2016; 26(11): 754–759. DOI: 10.1016/j.nmd.2016.10.002

10. Kolb S.J., Coffey C.S., Yankey J.W. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol 2017; 82: 883–891. DOI: 10.1002/ana.25101

11. Annoussamy M., Seferian A.M., Daron A., Péréon Y., Cances C., Vuillerot C. et al.; NatHis-SMA study group. Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann Clin Transl Neurol 2021; 8(2): 359–373. DOI: 10.1002/acn3.51281

12. Artemyeva S.B., Kuzenkova L.M., Ilyina E.S., Kursakova Yu.A., Kolpakchi L.M., Sapego E.Yu. et al. Efficacy and safety of nusinersen under the Expanded Access Program in Russia. Nervno-myshechnye bolezni 2020; 10 (3); 35–41. (in Russ.) DOI: 10.17650/2222–8721–2020–10–3–35–41; EDN: OUHJUQ.

13. Bofanova N.S., Eliseeva A.R., Onchina V.S. Current principles of therapy for patients with spinal muscular atrophies. Zhurnal nevrologii i psihiatrii im. C.C. Korsakova 2023; 123(3): 34–40. (in Russ.) DOI: 10.17116/jnevro202312303134; EDN: EILCJO.

14. Vlodavets D.V. Risdiplam in the treatment of spinal muscular atrophy. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova 2024; 124(2); 45–57. (in Russ.) DOI: 10.17116/jnevro202412402145; EDN: AITHVQ.

15. Paul G.R., Gushue C., Kotha K., Shell R. The respiratory impact of novel therapies for spinal muscular atrophy. Pediatr Pulmonol 2020; 56(4): 721–728. DOI: 10.1002/ppul.25135

16. Finkel R.S., Mercuri E., Darras B.T., Connolly A.M., Kuntz N.L., Kirschner J. et al.; ENDEAR Study Group. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med 2017; 377(18): 1723–1732. DOI: 10.1056/NEJMoa1702752. PMID: 29091570.

17. Day J.W., Finkel R.S., Chiriboga C.A., Connolly A.M., Crawford T.O., Darras B.T. et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 2021; 20(4): 284–293. DOI: 10.1016/S1474–4422(21)00001–6

18. Mercuri E., Muntoni F., Baranello G., Masson R., Boespflug-Tanguy O., Bruno C. et al.; STR1VE-EU study group. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 2021; 20(10): 832–841. DOI: 10.1016/S1474–4422(21)00251–9

19. Darras B.T., Masson R., Mazurkiewicz-Bełdzińska M., Rose K., Xiong H., Zanoteli E. et al. Risdiplam-treated infants with Type 1 spinal muscular atrophy versus historical controls. N Engl J Med 2021; 385(5): 427–435. DOI: 10.1056/NEJMoa2102047

20. Mercuri E., Darras B.T., Chiriboga C.A., Day J.W., Campbell C., Connolly A.M. et al.; CHERISH Study Group. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl J Med 2018; 378(7): 625–635. DOI: 10.1056/NEJMoa1710504

21. Oskoui M., Day J.W., Deconinck N., Mazzone E.S., Nascimento A., Saito K. et al.; SUNFISH Working Group. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J Neurol 2023; 270(5): 2531–2546. DOI: 10.1007/s00415–023–11560–1

22. Finkel R.S., Darras B.T., Mendell J.R., Day J.W., Kuntz N.L., Connolly A.M. et al. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG). J Neuromuscul Dis 2023; 10(3): 389–404. DOI: 10.3233/JND-221560

23. De Vivo D.C., Bertini E., Swoboda K.J., Hwu W.L., Crawford T.O., Finkel R.S. et al.; NURTURE Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 2019; 29(11): 842–856. DOI: 10.1016/j.nmd.2019.09.007

24. Strauss K.A., Farrar M.A., Muntoni F., Saito K., Mendell J.R., Servais L. et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med 2022; 28(7): 1381–1389. DOI: 10.1038/s41591–022–01866–4

25. Strauss K.A., Farrar M.A., Muntoni F., Saito K., Mendell J.R., Servais L. et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med 2022; 28(7): 1390–1397. DOI: 10.1038/s41591–022–01867–3

26. RAINBOWFISH Results Highlight Risdiplam as Effective Treatment for Presymptomatic SMA. https://www.ajmc.com/view/rainbowfish-results-highlight-risdiplam-as-effective-treatment-for-presymptomatic-sma

27. Prior T.W., Leach M.E., Finanger E. Spinal Muscular Atrophy. In: GeneReviews® [Internet]. Editors M.P. Adam, G.M. Mirzaa, R.A. Pagon, S.E. Wallace, L.J.H. Bean, K.W. Gripp et al., Seattle (WA): University of Washington, Seattle; 1993–2023.

28. Finkel R.S., Mercuri E., Meyer O.H., Simonds A.K., Schroth M.K., Graham R.J. et al.; SMA Care group. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord 2018; 28(3): 197–207. DOI: 10.1016/j.nmd.2017.11.004

29. Lemoine T.J., Swoboda K.J., Bratton S.L., Holubkov R., Mundorff M., Srivastava R. Spinal muscular atrophy type 1: are proactive respiratory interventions associated with longer survival? Pediatr Crit Care Med 2012; 13(3): e161–5. DOI: 10.1097/PCC.0b013e3182388ad1

30. Edel L., Grime C., Robinson V., Manzur A., Abel F., Munot P. et al. A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs. Neuromusc Dis 2021; 31(4): 300–309. DOI: 10.1016/j.nmd.2021.01.008

31. Chatwin M., Toussaint M., Gonçalves M.R., Sheers N., Mellies U., Gonzales-Bermejo J. et al. Airway clearance techniques in neuromuscular disorders: A state of the art review. Respir Med 2018; 136: 98–110. DOI: 10.1016/j.rmed.2018.01.012

32. Hull J., Aniapravan R., Chan E., Chatwin M., Forton J., Gallagher J. et al. British Thoracic Society guideline for respiratory management of children with neuromuscular weakness. Thorax 2012; 67 Suppl 1: i1–40. DOI: 10.1136/thoraxjnl-2012–201964